Chronic obstructive pulmonary disease exacerbation resident survival guide: Difference between revisions

Jump to navigation Jump to search
Line 89: Line 89:


* A systematic review found no significant differences in FEV<sub>1</sub> between MDI and nebulizers,<ref name="Turner-">{{Cite journal  | last1 = Turner | first1 = MO. | last2 = Patel | first2 = A. | last3 = Ginsburg | first3 = S. | last4 = FitzGerald | first4 = JM. | title = Bronchodilator delivery in acute airflow obstruction. A meta-analysis. | journal = Arch Intern Med | volume = 157 | issue = 15 | pages = 1736-44 | month =  | year =  | doi =  | PMID = 9250235 }}</ref> although the latter can be more convenient for sicker or frail patients.
* A systematic review found no significant differences in FEV<sub>1</sub> between MDI and nebulizers,<ref name="Turner-">{{Cite journal  | last1 = Turner | first1 = MO. | last2 = Patel | first2 = A. | last3 = Ginsburg | first3 = S. | last4 = FitzGerald | first4 = JM. | title = Bronchodilator delivery in acute airflow obstruction. A meta-analysis. | journal = Arch Intern Med | volume = 157 | issue = 15 | pages = 1736-44 | month =  | year =  | doi =  | PMID = 9250235 }}</ref> although the latter can be more convenient for sicker or frail patients.
=====Corticosteroids=====
* Systemic corticosteroids in COPD exacerbations shorten recovery time, improve FEV1 and PaO2,<ref name="Davies-1999">{{Cite journal  | last1 = Davies | first1 = L. | last2 = Angus | first2 = RM. | last3 = Calverley | first3 = PM. | title = Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. | journal = Lancet | volume = 354 | issue = 9177 | pages = 456-60 | month = Aug | year = 1999 | doi =  | PMID = 10465169 }}</ref><ref name="Maltais-2002">{{Cite journal  | last1 = Maltais | first1 = F. | last2 = Ostinelli | first2 = J. | last3 = Bourbeau | first3 = J. | last4 = Tonnel | first4 = AB. | last5 = Jacquemet | first5 = N. | last6 = Haddon | first6 = J. | last7 = Rouleau | first7 = M. | last8 = Boukhana | first8 = M. | last9 = Martinot | first9 = JB. | title = Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. | journal = Am J Respir Crit Care Med | volume = 165 | issue = 5 | pages = 698-703 | month = Mar | year = 2002 | doi = 10.1164/ajrccm.165.5.2109093 | PMID = 11874817 }}</ref><ref name="Niewoehner-1999">{{Cite journal  | last1 = Niewoehner | first1 = DE. | last2 = Erbland | first2 = ML. | last3 = Deupree | first3 = RH. | last4 = Collins | first4 = D. |last5 = Gross | first5 = NJ. | last6 = Light | first6 = RW. | last7 = Anderson | first7 = P. | last8 = Morgan | first8 = NA. | title = Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. | journal = N Engl J Med | volume = 340 | issue = 25 | pages = 1941-7| month = Jun | year = 1999 | doi = 10.1056/NEJM199906243402502 | PMID = 10379017 }}</ref><ref name="Thompson-1996">{{Cite journal  | last1 = Thompson | first1 = WH. | last2 = Nielson | first2 = CP. | last3 = Carvalho | first3 = P. | last4 = Charan | first4 = NB. | last5 = Crowley | first5 = JJ. | title = Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. | journal = Am J Respir Crit Care Med | volume = 154 | issue = 2 Pt 1 | pages = 407-12 | month = Aug | year = 1996 | doi = 10.1164/ajrccm.154.2.8756814 | PMID = 8756814 }}</ref> and reduce the risk of early relapse, treatment failure, and length of hospital stay.<ref name="Davies-1999">{{Cite journal  | last1 = Davies | first1 = L. | last2 = Angus | first2 = RM. | last3 = Calverley | first3 = PM. | title = Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. | journal = Lancet | volume = 354 | issue = 9177 | pages = 456-60 | month = Aug | year = 1999 | doi =  | PMID = 10465169 }}</ref><ref name="Niewoehner-1999">{{Cite journal  | last1 = Niewoehner | first1 = DE. | last2 = Erbland | first2 = ML. | last3 = Deupree | first3 = RH. | last4 = Collins | first4 = D. | last5 = Gross | first5 = NJ. | last6 = Light | first6 = RW. | last7 = Anderson | first7 = P. | last8 = Morgan| first8 = NA. | title = Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. |journal = N Engl J Med | volume = 340 | issue = 25 | pages = 1941-7 | month = Jun | year = 1999 | doi = 10.1056/NEJM199906243402502 | PMID = 10379017 }}</ref><ref name="Aaron-2003">{{Cite journal  | last1 = Aaron | first1 = SD. | last2 = Vandemheen | first2 = KL. | last3 = Hebert | first3 = P. | last4 = Dales | first4 = R. | last5 = Stiell | first5 = IG. |last6 = Ahuja | first6 = J. | last7 = Dickinson | first7 = G. | last8 = Brison | first8 = R. | last9 = Rowe | first9 = BH. | title = Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. | journal = N Engl J Med | volume = 348 | issue = 26 | pages = 2618-25 | month = Jun | year = 2003 | doi = 10.1056/NEJMoa023161 |PMID = 12826636 }}</ref>


=====Antibiotics=====
=====Antibiotics=====

Revision as of 04:22, 15 December 2013

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

Definition

  • Exacerbation of COPD is an acute event characterized by a worsening of the patient’s respiratory symptoms that is beyond normal day-to-day variations and leads to a change in medication.[1][2][3]
  • The diagnosis of an exacerbation relies exclusively on the clinical presentation of the patient complaining of an acute change of symptoms (baseline dyspnea, cough, and/or sputum production) that is beyond normal day-to-day variation.[4]

Causes

Life-Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

Common Causes

Treatment Setting and Severity

COPD Exacerbation
❑ Cough ↑
❑ Dyspnea ↑
❑ Sputum ↑
 
 
 
 
1. Oxygen Supplement
❑ Pulse oximetry (maintain SaO2 ≥88—92%)[5]
❑ Arterial blood gas (if acute or acute-on-chronic respiratory failure is suspected)
 
 
 
 
 
2. Indications for ICU Admission
❑ Hemodynamic instability
❑ Changes in mental status (confusion, lethargy, coma)
❑ Severe dyspnea that responds inadequately to initial emergency therapy
❑ Worsening hypoxemia (PaO2 <40 mm Hg) and/or respiratory acidosis (pH <7.25)
 
 
 
 
 
 
 
 
 
 
2a. Indications for Noninvasive Mechanical Ventilation
❑ Respiratory acidosis (arterial pH < 7.35 or PaCO2 >45 mm Hg)
❑ Severe dyspnea with sings of respiratory muscle fatigue
❑ Increased work of breathing
2b. Indications for Invasive Mechanical Ventilation
❑ Diminished consciousness, psychomotor agitation inadequately controlled by sedation
❑ Severe hemodynamic instability without response to fluids and vasoactive drugs
❑ Respiratory pauses with loss of consciousness or gasping for air
❑ Life-threatening hypoxemia in patients unable to tolerate NIV
❑ Persistent inability to remove respiratory secretions
❑ Heart rate <50/min with loss of alertness
❑ Unable to tolerate NIV or NIV failure
❑ Severe ventricular arrhythmias
❑ Respiratory or cardiac arrest
❑ Massive aspiration
 
 
 
 

3. Indications for Hospitalization
❑ Marked increase in intensity of symptoms (eg, sudden development of resting dyspnea)
❑ Presence of serious comorbidities (eg, heart failure or newly occurring arrhythmias)
❑ Failure of an exacerbation to respond to initial medical management
❑ Onset of new physical signs (eg, cyanosis, peripheral edema)
❑ Severe underlying COPD (GOLD 3—4 categories)
❑ Frequent exacerbations (≥2 events per year)
❑ Insufficient home support
❑ Older age (>65 years)


4. Assessment of Severity of Exacerbation
❑ Sputum purulence
❑ ECG (identify coexisting cardiac problems)
❑ Chest radiograph (exclude alternative diagnoses)
❑ Whole-blood count (identify polycythemia, anemia, or leukocytosis)
❑ Electrolytes and glucose (identify electrolyte disturbances or hyperglycemia)
 
 
 
 
 
 
 
 
 

Severe Exacerbation
❑ Consider inpatient management
❑ Assess symptoms, ABG, and CXR
❑ Monitor fluid balance and nutrition
❑ Identify and treat associated conditions
❑ Consider subcutaneous heparin or LMWH
❑ Controlled oxygen therapy (use NIV if indicated)
❑ Antibiotics (if ↑ sputum purulence or ⊕ bacterial infection)
❑ Corticosteroids
❑ Bronchodilators
▸ Increase doses/frequency of short-acting bronchodilators
▸ Combine short-acting β2-agonists and anticholinergics
▸ Use spacers or air-driven nebulizers


Moderate Exacerbation
❑ Consider outpatient management
❑ Require a short course of antibiotics or oral corticosteroids


Mild Exacerbation
❑ Consider outpatient management
❑ Require change of inhaled treatment by the patient

Management

Do's

Assessment

  • The presence of purulent sputum during an exacerbation can be sufficient indication for starting empirical antibiotic treatment.[6]

Treatment

Treatment Setting
  • When a patient comes to the ED, the first actions are to provide controlled oxygen therapy and to determine whether the exacerbation is life threatening. If so, the patient should be admitted to the ICU immediately.[4]
Short-Acting Bronchodilators
  • Short-acting inhaled β2-agonists with or without short-acting anticholinergics are usually the preferred bronchodilators for treatment of an exacerbation.[7]
  • A systematic review found no significant differences in FEV1 between MDI and nebulizers,[8] although the latter can be more convenient for sicker or frail patients.
Corticosteroids
  • Systemic corticosteroids in COPD exacerbations shorten recovery time, improve FEV1 and PaO2,[9][10][11][12] and reduce the risk of early relapse, treatment failure, and length of hospital stay.[9][11][13]


Antibiotics

Don'ts

Assessment

  • Spirometry is not recommended during an exacerbation because it can be difficult to perform and measurements are not accurate enough.

References

  1. Burge, S.; Wedzicha, JA. (2003). "COPD exacerbations: definitions and classifications". Eur Respir J Suppl. 41: 46s–53s. PMID 12795331. Unknown parameter |month= ignored (help)
  2. Celli, BR.; Barnes, PJ. (2007). "Exacerbations of chronic obstructive pulmonary disease". Eur Respir J. 29 (6): 1224–38. doi:10.1183/09031936.00109906. PMID 17540785. Unknown parameter |month= ignored (help)
  3. Rodriguez-Roisin, R. (2000). "Toward a consensus definition for COPD exacerbations". Chest. 117 (5 Suppl 2): 398S–401S. PMID 10843984. Unknown parameter |month= ignored (help)
  4. 4.0 4.1 4.2 Vestbo, J.; Hurd, SS.; Agustí, AG.; Jones, PW.; Vogelmeier, C.; Anzueto, A.; Barnes, PJ.; Fabbri, LM.; Martinez, FJ. (2013). "Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary". Am J Respir Crit Care Med. 187 (4): 347–65. doi:10.1164/rccm.201204-0596PP. PMID 22878278. Unknown parameter |month= ignored (help)
  5. Austin, MA.; Wills, KE.; Blizzard, L.; Walters, EH.; Wood-Baker, R. (2010). "Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial". BMJ. 341: c5462. PMID 20959284.
  6. Stockley, RA.; O'Brien, C.; Pye, A.; Hill, SL. (2000). "Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD". Chest. 117 (6): 1638–45. PMID 10858396. Unknown parameter |month= ignored (help)
  7. Celli, BR.; MacNee, W. (2004). "Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper". Eur Respir J. 23 (6): 932–46. PMID 15219010. Unknown parameter |month= ignored (help)
  8. Turner, MO.; Patel, A.; Ginsburg, S.; FitzGerald, JM. "Bronchodilator delivery in acute airflow obstruction. A meta-analysis". Arch Intern Med. 157 (15): 1736–44. PMID 9250235.
  9. 9.0 9.1 Davies, L.; Angus, RM.; Calverley, PM. (1999). "Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial". Lancet. 354 (9177): 456–60. PMID 10465169. Unknown parameter |month= ignored (help)
  10. Maltais, F.; Ostinelli, J.; Bourbeau, J.; Tonnel, AB.; Jacquemet, N.; Haddon, J.; Rouleau, M.; Boukhana, M.; Martinot, JB. (2002). "Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial". Am J Respir Crit Care Med. 165 (5): 698–703. doi:10.1164/ajrccm.165.5.2109093. PMID 11874817. Unknown parameter |month= ignored (help)
  11. 11.0 11.1 Niewoehner, DE.; Erbland, ML.; Deupree, RH.; Collins, D.; Gross, NJ.; Light, RW.; Anderson, P.; Morgan, NA. (1999). "Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group". N Engl J Med. 340 (25): 1941–7. doi:10.1056/NEJM199906243402502. PMID 10379017. Unknown parameter |month= ignored (help)
  12. Thompson, WH.; Nielson, CP.; Carvalho, P.; Charan, NB.; Crowley, JJ. (1996). "Controlled trial of oral prednisone in outpatients with acute COPD exacerbation". Am J Respir Crit Care Med. 154 (2 Pt 1): 407–12. doi:10.1164/ajrccm.154.2.8756814. PMID 8756814. Unknown parameter |month= ignored (help)
  13. Aaron, SD.; Vandemheen, KL.; Hebert, P.; Dales, R.; Stiell, IG.; Ahuja, J.; Dickinson, G.; Brison, R.; Rowe, BH. (2003). "Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease". N Engl J Med. 348 (26): 2618–25. doi:10.1056/NEJMoa023161. PMID 12826636. Unknown parameter |month= ignored (help)
  14. Sethi, S.; Murphy, TF. (2008). "Infection in the pathogenesis and course of chronic obstructive pulmonary disease". N Engl J Med. 359 (22): 2355–65. doi:10.1056/NEJMra0800353. PMID 19038881. Unknown parameter |month= ignored (help)